|AHFS/Drugs.com||Micromedex Detailed Consumer Information|
|ATC code||P02BA02 (WHO) QP52AA02 (WHO)|
|Bioavailability||Readily absorbed when taken by mouth|
|Biological half-life||1 to 2.5h|
|Excretion||mainly in urine|
|PDB ligand ID||OAQ (PDBe, RCSB PDB)|
|Chemical and physical data|
|3D model (Jmol)||Interactive image|
|(what is this?)|
Oxamniquine, sold under the brand name Vansil among others, is a medication used to treat schistosomiasis due to Schistosoma mansoni. Praziquantel; however, is often the preferred treatment. It is given by mouth and used as a single dose.
Common side effects include sleepiness, headache, nausea, diarrhea, and reddish urine. It is typically recommended that it not be used until after pregnancy if possible. Seizures may occur and therefore caution is recommended in people with epilepsy. It works by causes paralyses of the parasitic worms. It is in the anthelmintic family of medications.
Oxamniquine was first used medically in 1972. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. It is not commercially available in the United States. It is more expensive than praziquantel.
It is generally well tolerated following oral doses. Dizziness with or without drowsiness occurs in at least a third of patients, beginning up to three hours after a dose, and usually lasts for up to six hours. Headache and gastrointestinal effects, such as nausea, vomiting, and diarrhoea, are also common.
Allergic-type reactions, including urticaria, pruritic skin rashes, and fever, may occur. Liver enzyme values have been raised transiently in some patients. Epileptiform convulsions have been reported, especially in patients with a history of convulsive disorders. Hallucinations and excitement have occurred rarely.
A reddish discoloration of urine, probably due to a metabolite of oxamniquine, has been reported.
Oxamniquine is not recommended during pregnancy.
Peak plasma concentrations are achieved one to three hours after a dose, and the plasma half-life is 1.0 to 2.5 hours.
It is extensively metabolised to inactive metabolites, principally the 6-carboxy derivative, which are excreted in the urine. About 70% of a dose of oxamniquine is excreted as the 6-carboxy metabolite within 12 hours of a dose; traces of the 2-carboxy metabolite have also been detected in the urine.
Mechanism of action
It is an anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine is a potent single-dose agent for treatment of S. mansoni infection, and it causes worms to shift from the mesenteric veins to the liver, where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs.
Oxamniquine is a semisynthetic tetrahydroquinoline and possibly acts by DNA binding, resulting in contraction and paralysis of the worms and eventual detachment from terminal venules in the mesentry, and death. Its biochemical mechanisms are hypothesized to be related to an anticholinergic effect, which increases the parasite’s motility, as well as to synthesis inhibition of nucleic acids. Oxamniquine acts mainly on male worms, but also induces small changes on a small proportion of females. Like praziquantel, it promotes more severe damage of the dorsal tegument than of the ventral surface. The drug causes the male worms to shift from the mesenteric circulation to the liver, where the cellular host response causes its final elimination. The changes caused in the females are reversible and are due primarily to the discontinued male stimulation rather than the direct effect of oxamniquine.
Oxamniquine was first described by Kaye and Woolhouse in 1972 as a metabolite of the compound UK 3883 (2-isopropylaminomethyl-6-methyl-7-nitro-1,2,3,4-tetrahydroquinoline). Initially, it was prepared by microbiological hydroxylation in the presence of the fungus Aspergillus sclerotiorum. In 1979, Pfizer at Sandwich was presented with the Queen's Award for Technological Achievement in recognition of the outstanding contribution made to tropical medicine by MANSIL (oxamniquine).
- Vansil; (Pfizer) 250 mg capsules, syrup 250 mg/5 mL
- Mansil; 250 mg Tablets
- WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 94. ISBN 9789241547659. Retrieved 8 December 2016.
- Griffiths, Jeffrey; Maguire, James H.; Heggenhougen, Kristian; Quah, Stella R. (2010). Public Health and Infectious Diseases. Elsevier. p. 351. ISBN 9780123815071.
- Cohen, Jonathan; Powderly, William G.; Opal, Steven M. (2016). Infectious Diseases (4 ed.). Elsevier Health Sciences. p. 1371. ISBN 9780702063381.
- "Oxamniquine medical facts from Drugs.com". www.drugs.com. Retrieved 10 December 2016.
- Jordan, Peter (1985). Schistosomiasis: The St Lucia Project. CUP Archive. p. 298. ISBN 9780521303125.
- "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
- "International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026: Chapter 2: Bayer & E. Merck: Discovery and development of praziquantel*: Competing drugs for schistosomiasis treatment". apps.who.int. Retrieved 10 December 2016.
- Martidale, The Extra Pharmacopoeia, 31st ed, p121
- AHFS Database